| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 topline data readout example | Phase 1 | — | Subscribe to access the data. | Biologics | Endocrine System | ||
Phase 1 topline data readout example | Phase 1 | — | Subscribe to access the data. | Biologics | Endocrine System | ||
Phase 1 topline data readout example | Phase 1 | — | Subscribe to access the data. | Biologics | Endocrine System |
Recent Updates
Recently added Catalysts
Yarrow Bioscience, Inc. Common Stock
$25.54
-0.53 (-2.03%)
D 26Pipeline Score Overvalued Biotech · Clinical
Market Cap
68.19 M
EPS
-
P/E Ratio
-
Value Trade
942.12 K
-9.75 %
Week
-30.97 %
1 Month
-8.95 %
3 Month
-8.95 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
474.17 K
52 Week Range
-
% held by Insiders
11.97 %
% held by Institutions
9.1 %
Enterprise Value
45.26 M
Total Shares
2.67 M
Short %
1.52 %
Float Shares
8.31 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Yarrow Bioscience, Inc. Common Stock
18Total events
7Upcoming
4Tier-1 (high impact)
2026 – 2028Coverage
Upcoming catalysts 2
TBD
T1Topline Readout
Subscribe to view catalyst details
TBD
T1Topline Readout
Subscribe to view catalyst details
Event history 2
TBD
▼Equity OfferingCorporate
Subscribe to view catalyst details
TBD
▼Equity OfferingCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
D26
Pipeline Score $29M
Pipeline ValueOvervalued
Valuation Signal1
Drugs Scored0.4x
rNPV / MCap Top 19%
Micro Cap (rank 532 of 655)
Percentile RankYarrow Bioscience, Inc. Common Stock faces pipeline headwinds (26/100), with $114M risk-adjusted pipeline value, led by YB-101 in Graves' Disease (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| YB-101 Small molecule | Graves' Disease | Phase 2 | NCT07682896 | 7% | $114M | RECRUITING | 232 | VERY_FAST | B (64) | Sep 1, 2029 | - | Sep 4, 2026 |
YARW Clinical Trial Results & History
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
INSIDER TRANSACTIONSMonthly totals, since 2023
BuysSellsStock price
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in YARW
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
YARW Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-YARW
Sep 14, 2026Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Yarrow Bioscience has successfully closed its underwritten public offering, raising $172.5 million by selling 6,634,615 shares at $26.00 each. This includes the full exercise of the underwriters' option for an additional 865,384 shares. The funds will support the company's focus on developing therapies for autoimmune thyroid diseases.
Read more →-YARW
Sep 11, 2026▼ -5%on this newsshared move
Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering
Yarrow Bioscience has announced the pricing of its underwritten public offering, selling 5,769,231 shares of common stock at $26.00 per share. This offering is expected to raise approximately $150 million for the company. Yarrow focuses on developing transformative therapies for autoimmune thyroid diseases.
Read more →-YARW
Sep 10, 2026▼ -5%on this newsshared move
Yarrow Bioscience Announces Proposed Underwritten Public Offering
Yarrow Bioscience, a clinical-stage biotechnology firm, has announced a proposed underwritten public offering of its common stock. The offering may include pre-funded warrants for certain investors. This move aims to bolster the company's financial resources as it develops therapies for autoimmune thyroid diseases.
Read more →-YARW
Aug 13, 2026Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update
Yarrow Bioscience has announced its financial results for the second quarter of 2026. The report includes insights into the company's performance and ongoing business developments. This update reflects Yarrow's commitment to transparency and stakeholder engagement.
Read more →Competitive Position
How YARW ranks across every disease it competes inCompetitive Position is a premium feature
See how YARW ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial